Company,Name,Other name,Potential Indication,Phase,NCT Number,Status,URL
Gilead Sciences,GS-9674,FXR agonist,NASH,Phase 2,NCT02854605,Completed,https://ClinicalTrials.gov/show/NCT02854605
Gilead Sciences,GS-9674,FXR agonist,NASH,Phase 2,NCT02781584,Recruiting,https://ClinicalTrials.gov/show/NCT02781584
Gilead Sciences,GS-9674,FXR agonist,NASH,Phase 2,NCT03449446,Recruiting,https://ClinicalTrials.gov/show/NCT03449446
Gilead Sciences,GS-9674,FXR agonist,Primary Biliary Cirrhosis,Phase 2,NCT02943447,"Active, not recruiting",https://ClinicalTrials.gov/show/NCT02943447
Gilead Sciences,GS-9674,FXR agonist,Primary Sclerosing Cholangitis,Phase 2,NCT02943460,"Active, not recruiting",https://ClinicalTrials.gov/show/NCT02943460
